SMS Pharmaceuticals on Thursday has announced the successful closure of inspection with the receipt of Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA).
The inspection was conducted by the USFDA at its API facility Kandivalasa, Andhra Pradesh, during January 13-17, the company said.
This facility predominantly caters to regulated markets including the US, it said.
The stock is currently trading at Rs33, down by Rs1.4 or 4.07% from its previous closing of Rs34.40 on the BSE.
The scrip opened at Rs34.95 and has touched a high and low of Rs35.30 and Rs33 respectively.
The inspection was conducted by the USFDA at its API facility Kandivalasa, Andhra Pradesh, during January 13-17, the company said.
This facility predominantly caters to regulated markets including the US, it said.
The stock is currently trading at Rs33, down by Rs1.4 or 4.07% from its previous closing of Rs34.40 on the BSE.
The scrip opened at Rs34.95 and has touched a high and low of Rs35.30 and Rs33 respectively.
0 comments:
Post a Comment
Please add comment